Andrew Wirth

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi PET for follicular lymphoma: a work in progress!
    Andrew Wirth
    Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria, Australia
    Leuk Lymphoma 48:1463-4. 2007
  2. ncbi The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era
    Andrew Wirth
    Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Leuk Lymphoma 48:2121-36. 2007
  3. ncbi Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
    Andrew Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 71:213-9. 2008
  4. ncbi Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group
    Andrew Wirth
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer 104:1221-9. 2005
  5. ncbi Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study
    A Wirth
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    Bone Marrow Transplant 35:291-8. 2005
  6. ncbi Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group
    Andrew Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    Leuk Lymphoma 52:786-95. 2011
  7. ncbi Phantom measurements and computed estimates of breast dose with radiotherapy for Hodgkin's lymphoma: dose reduction with the use of the involved field
    A Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Med Imaging Radiat Oncol 52:394-402. 2008
  8. ncbi Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer
    Marie Pierre Campeau
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 74:1371-5. 2009
  9. ncbi Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 49:95-108. 2005
  10. ncbi Long-term survival following chemoradiation for inoperable non-small cell lung cancer
    Nikki M Plumridge
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Med J Aust 189:557-9. 2008

Collaborators

Detail Information

Publications24

  1. ncbi PET for follicular lymphoma: a work in progress!
    Andrew Wirth
    Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria, Australia
    Leuk Lymphoma 48:1463-4. 2007
  2. ncbi The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era
    Andrew Wirth
    Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Leuk Lymphoma 48:2121-36. 2007
    ....
  3. ncbi Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
    Andrew Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 71:213-9. 2008
    ..We evaluated the impact of fluorodeoxyglucose (FDG) PET on staging, treatment, and outcome for patients with ESFL on conventional staging...
  4. ncbi Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group
    Andrew Wirth
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer 104:1221-9. 2005
    ..The curative potential of radiotherapy (RT) alone as initial treatment for patients with Stage I-II lymphocyte-predominant Hodgkin lymphoma (LPHL) has not been defined well...
  5. ncbi Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study
    A Wirth
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    Bone Marrow Transplant 35:291-8. 2005
    ..As sequenced in this study, IFRT was feasible and produced a low incidence of severe pulmonary and haematological toxicities. Patient selection, field size and radiotherapy dose warrant further study...
  6. ncbi Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group
    Andrew Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    Leuk Lymphoma 52:786-95. 2011
    ..05). The 97% FFP in group 1 compares favorably with previously reported results from cooperative trial groups. Intensification of therapy warrants study in patients with RF and a poor chemotherapy response...
  7. ncbi Phantom measurements and computed estimates of breast dose with radiotherapy for Hodgkin's lymphoma: dose reduction with the use of the involved field
    A Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Med Imaging Radiat Oncol 52:394-402. 2008
    ..Computer dosimetery underestimated dose at larger distances from the field. This needs to be considered if computer dosimetery is used to estimate breast dose and, by extrapolation, breast cancer risk...
  8. ncbi Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer
    Marie Pierre Campeau
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 74:1371-5. 2009
    ..The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients...
  9. ncbi Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 49:95-108. 2005
    ..PET-response, survival and patterns of failure data are presented with long-term follow-up...
  10. ncbi Long-term survival following chemoradiation for inoperable non-small cell lung cancer
    Nikki M Plumridge
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Med J Aust 189:557-9. 2008
    ..To measure long-term survival following combined chemotherapy and radiotherapy for inoperable non-small cell lung cancer...
  11. ncbi Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
    Ashley P Ng
    Haematology Service, PeterMacCallum Cancer Centre, Melbourne, Australia
    Leuk Lymphoma 48:596-600. 2007
    ..Low-grade FDG-avidity on interim restaging at sites of bone involvement by DLBCL at diagnosis, appears to be less predictive of disease progression than residual nodal or extra-nodal soft tissue abnormality by PET...
  12. ncbi Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    Andrew Wirth
    Division of Radiation Oncology, Peter McCallum Cancer Institute, East Melbourne, Victoria, Australia
    Am J Med 112:262-8. 2002
    ..These data support the use of PET in place of gallium scanning for the staging of patients with Hodgkin's disease or non-Hodgkin's lymphoma...
  13. ncbi Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma
    Robert H Blum
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Clin Lymphoma 4:43-9. 2003
    ..This high accuracy of FDG-PET in assessing discordant lesions suggests a greater diagnostic utility compared with CT...
  14. ncbi Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience
    Michael Ng
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Thorac Oncol 2:506-13. 2007
    ..We have reviewed the experience at Peter MacCallum Cancer Centre to determine the tolerability of these treatments in routine practice and to determine their effects on survival...
  15. ncbi FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden
    Michael R MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Acta Oncol 42:48-54. 2003
    ..027) but not pre-PET stage, weight loss or metastasis site correlated with survival. PET-detected metastatic tumor burden appeared to influence survival and should be evaluated as a prognostic factor in NSCLC...
  16. ncbi Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
    Cancer 106:1110-6. 2006
    ..We used a very large prospective database to estimate the frequency of this phenomenon and to look for correlative prognostic factors...
  17. ncbi Mantle cell lymphoma with central nervous system involvement: frequency and clinical features
    Saar Gill
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Br J Haematol 147:83-8. 2009
    ..While not routinely justified for all patients, CNS prophylaxis may particularly benefit patients with blastic histology at diagnosis, or those with systemic relapse after first-line treatment...
  18. ncbi Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure
    Belinda Campbell
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 63:1538-45. 2005
    ..CONCLUSIONS: Salvage radiotherapy is effective for selected patients with Hodgkin's lymphoma after chemotherapy failure and should be considered for incorporation into salvage programs...
  19. ncbi Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy
    Michael Fay
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 61:1355-63. 2005
    ..V(30) correlated highly positively with MLD (r = 0.96, p < 0.001). CONCLUSION: V(30) and MLD can be used to predict the risk of RP in lung cancer patients undergoing radical radiotherapy...
  20. ncbi Measurement of lung tumor volumes using three-dimensional computer planning software
    Patrick Bowden
    Division of Radiation Oncology, Peter MacCallum Cancer Institute, A'Beckett Street, Melbourne, Victoria 8006, Australia
    Int J Radiat Oncol Biol Phys 53:566-73. 2002
    ..Standardization of the approach with guidelines resulted in a reduction in this variation...
  21. ncbi Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 52:351-61. 2002
    ..We hypothesized that early cancer death rates would be lower in patients receiving RRT after PET staging compared with conventionally staged patients...
  22. ncbi Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma
    Krystel H Tran
    Peter MacCallum Cancer Centre Division of Radiation Oncology and Cancer Imaging, East Melbourne, Vic, Australia
    Leuk Lymphoma 54:491-6. 2013
    ..Aside from cataractogenesis, there was no significant late toxicity. Our study shows that RT doses of 24-25 Gy provide high rates of LC for orbital MZL with acceptable morbidity...
  23. ncbi Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05)
    Daniel E Roos
    Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
    Radiother Oncol 80:318-22. 2006
    ..Our results are not inconsistent with two larger randomized trials and support the use of upfront WBI to decrease brain recurrence in this setting...
  24. ncbi PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy
    Kenneth B Roberts
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA
    Lung Cancer 47:49-57. 2005
    ..PET may be valuable after pneumonectomy if the patient is being considered for adjuvant or salvage radiotherapy although specificity may be reduced due to post-operative inflammatory changes...